AIM ImmunoTech vs Inmune Bio
AIM and INMB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AIM and INMB compare
Inmune Bio is the larger company, worth 6.7 times as much as AIM ImmunoTech ($29.1M against $4.4M).
Inmune Bio scores higher on the StockData Score (6 against 3 for AIM ImmunoTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AIM | INMB |
|---|---|---|
| Size and price | ||
| Market cap | $4.4M | $29.1M |
| Share price | $0.144 | $1.05 |
| Change, 1 year | −90.9% | −30.9% |
| Change, 5 years | −99.9% | −92.1% |
| Beta (5Y) | 0.83 | 1.32 |
| Employees | – | 6 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 48.0× | – |
| P/B | 0.6× (better) | 1.6× |
| Growth | ||
| Revenue growth (TTM) | −18.8% | – |
| Revenue growth, 5Y average | −11.6% | 35.4% (better) |
| Profitability | ||
| Operating margin | −12800% | – |
| Net margin | −15526% | – |
| Return on equity | −2829% | −76.7% (better) |
| Financial health | ||
| Debt / equity | 0.20 (better) | 0.00 |
| Interest coverage | −14.3× | – |
| Current ratio | 2.75 | 6.41 (better) |
| Altman Z-score | −67.09 | −11.10 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 3.8% | 15.7% |
| Held by insiders | 13.0% | 16.7% |
| Insider net buying, 12 months | $39.3K | – |
| Short interest, % of float | 3.8% | 11.5% |
Go deeper
- AIM stock overview
- AIM income statement
- AIM valuation and score
- INMB stock overview
- INMB income statement
- INMB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.